MAP2K7
MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.
CIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Tamoxifen and Fulvestrant. IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Stomach Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway.
- 3 · How drugs use it
No product in this corpus aims at MAP2K7 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:6847 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14733 (protein name, function text, keywords and locations (REST API)); CIViC gene MAP2K7 (4 evidence items, 0 assertions, 3 variants; diseases: Oestrogen Receptor-positive Breast Cancer, Lung Cancer (GraphQL API, CC0)); IntOGen MAP2K7 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Location: Nucleus; Cytoplasm (UniProt). Locus 19p13.2 (HGNC).
- Lung cancer: CIViC evidence names this disease
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)
- HR-positive / HER2-negative breast cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MAP2K7" OR ABSTRACT:"MAP2K7" OR TITLE:"mitogen-activated protein kinase kinase 7" OR ABSTRACT:"mitogen-activated protein kinase kinase 7" OR TITLE:"Dual specificity mitogen-activated protein kinase kinase 7" OR ABSTRACT:"Dual specificity mitogen-activated protein kinase kinase 7" OR TITLE:"MKK7" OR ABSTRACT:"MKK7" OR TITLE:"Jnkk2" OR ABSTRACT:"Jnkk2" OR TITLE:"SAPKK4" OR ABSTRACT:"SAPKK4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAP2K7, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetAIMP2
Shares Lung cancer (all types), CIViC.
- TargetPDCD4
Shares Lung cancer (all types), CIViC.
- TargetTP53BP1
Shares Lung cancer (all types), CIViC.
- TargetETV1
Shares Lung cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetRASA1
Shares Lung cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetBARD1
Shares Lung cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetETV4
Shares Lung cancer (all types), CIViC, IntOGen.
- TargetKDM6A
Shares Lung cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.